Lys164
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.7
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys164  -  HOXA10 (human)

Site Information
CSFAQNIkEESSYCL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1873286912

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
endometrial cancer ( 1 ) , endometrial adenocarcinoma ( 1 ) , urethral cancer ( 1 )
Relevant cell line - cell type - tissue:
BeWo ( 1 ) , endometrium ( 1 ) , HEK293T (epithelial) ( 1 ) , Ishikawa (endometrial) ( 1 )

Upstream Regulation
Treatments:
estradiol ( 1 ) , progesterone ( 1 )

Downstream Regulation
Effects of modification on HOXA10:
acetylation ( 1 ) , molecular association, regulation ( 1 ) , protein degradation ( 1 )
Effects of modification on biological processes:
cell adhesion, inhibited ( 1 ) , transcription, inhibited ( 1 )
Inhibit interaction with:
DNA ( 1 )

References 

1

Jiang R, et al. (2017) Enhanced HOXA10 sumoylation inhibits embryo implantation in women with recurrent implantation failure. Cell Death Discov 3, 17057
29018572   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.